Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials

Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials

<i>Context</i>: Several recent randomized controlled trials (RCTs) have reported on the survival benefits of poly (ADP-ribose) polymerase inhibitors (PARPi) compared to standard-of-care (SOC) treatment (enzalutamide, abiraterone, or docetaxel) in patients with metastatic castration-resis...

Full description

Bibliographic Details
Main Authors: Zheng Chao, Zefeng Wang, Le Li, Yi Jiang, Yunxing Tang, Yanan Wang, Xiaodong Hao, Chunyu Zhang, Xiangdong Guo, Weimin Yu, Fan Cheng, Zhihua Wang
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Medicina
Subjects:
prostate cancer
PARP inhibitors
survival
adverse events
meta-analysis
Online Access:https://www.mdpi.com/1648-9144/59/12/2198

Internet

https://www.mdpi.com/1648-9144/59/12/2198

Similar Items